The potential of LINGO-1 as a therapeutic target for essential tremor

Expert Opinion on Therapeutic Targets

Volumn 19, Issue 8, 2015, Pages 1139-1148

  Agundez, Jose Ag ^a,b   Jimenez Jimenez, Felix Javier ^c   Alonso Navarro, Hortensia ^c   Garcia Martin, Elena ^a,b  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b RIRAAF   (Spain)

^c Hospital Universitario del Sureste de Madrid   (Spain)

Author keywords

BIIB033; clinical trials; essential tremor; genetic linkage; Li81; LINGO 1

Indexed keywords

LINGO 1 PROTEIN; OPICINUMAB; PROTEIN; UNCLASSIFIED DRUG; ANTIBODY; LINGO1 PROTEIN, HUMAN; MEMBRANE PROTEIN; NERVE PROTEIN;

AMINO ACID SUBSTITUTION; CELL DIFFERENTIATION; CLINICAL FEATURE; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; ESSENTIAL TREMOR; GENE FREQUENCY; GENETIC LINKAGE; GENETIC VARIABILITY; GENOME; HUMAN; MISSENSE MUTATION; NEXT GENERATION SEQUENCING; OLIGODENDROGLIA; PHASE 1 CLINICAL TRIAL (TOPIC); PROMOTER REGION; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; GENETIC VARIATION; GENETICS; METABOLISM; MULTIPLE SCLEROSIS; NEURODEGENERATIVE DISEASES; PATHOPHYSIOLOGY;

ANIMALS; ANTIBODIES; ESSENTIAL TREMOR; GENETIC VARIATION; HUMANS; MEMBRANE PROTEINS; MULTIPLE SCLEROSIS; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES;

EID: 84937152225     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2015.1028360     Document Type: Review

References (90)

1. Elias WJ, Shah BB. Tremor. JAMA 2014;311(9):948-54
2. Louis ED. Essential tremor. Lancet Neurol 2005;4(2):100-10
3. Alonso-Navarro H, Benito-León J, Vázquez-Rodŕguez A, et al. Temblor esencial. In: Jim-enez-Jim-enez FJ, Luquin MR, Molina JA, Linazasoro G, editors. Tratado de los trastornos del movimiento, 1. Viguera Editores; Barcelona: 2008. p. 833-86
4. Jankovic J. Essential tremor: a heterogenous disorder. Mov Disord 2002;17(4):638-44
5. Koller W, Biary N, Cone S. Disability in essential tremor: effect of treatment. Neurology 1986;36(7):1001-4
6. Busenbark KL, Nash J, Nash S, et al. Is essential tremor benign Neurology 1991;41(12):1982-3
7. Louis ED. Etiology of essential tremor: should we be searching for environmental causes Mov Disord 2001;16(5):822-9
8. Salemi G, Aridon P, Calagna G, et al. Population-based case-control study of essential tremor. Ital J Neurol Sci 1998;19(5):301-5
9. Louis ED, Zheng W, Jurewicz EC, et al. Elevation of blood beta-carboline alkaloids in essential tremor. Neurology 2002;59(12):1940-4
10. Jimenez-Jimenez FJ, de Toledo-Heras M, Alonso-Navarro H, et al. Environmental risk factors for essential tremor. Eur Neurol 2007;58(2):106-13
11. Martinez C, Garcia-Martin E, Alonso-Navarro H, et al. Glutathione-S-transferase P1 polymorphism and risk for essential tremor. Eur J Neurol 2008;15(3):234-8
12. Louis ED. Environmental epidemiology of essential tremor. Neuroepidemiology 2008;31(3):139-49
13. Alonso-Navarro H, Jimenez-Jimenez FJ, Garcia-Martin E, Agundez JA; Neurochemistry and Neuropharmacology of Essential Tremor 2013 Feb. Frontiers in Clinical Drug Research-CNS and Neurological Disorders [Internet]. 2014/04/04. [110-42]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24694231
14. Zesiewicz TA, Elble RJ, Louis ED, et al. Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology. Neurology 2011;77(19):1752-5
15. Zappia M, Albanese A, Bruno E, et al. Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association. J Neurol 2013;260(3):714-40
16. Jefferson D, Wharrad HJ, Birmingham AT, Patrick JM. The comparative effects of ICI 118551 and propranolol on essential tremor. Br J Clin Pharmacol 1987;24(6):729-34
17. Manto M, Laute MA. A possible mechanism for the beneficial effect of ethanol in essential tremor. Eur J Neurol 2008;15(7):697-705
18. Knudsen K, Lorenz D, Deuschl G. A clinical test for the alcohol sensitivity of essential tremor. Mov Disord 2011;26(12):2291-5
19. Martinez C, Garcia-Martin E, Alonso-Navarro H, et al. Alcohol dehydrogenase 2 genotype and allelic variants are not associated with the risk for essential tremor. Clin Neuropharmacol 2007;30(4):196-200
20. Ulmanova O, Vinopalova M, Zima T, Ruzicka E. Biomarkers demonstrate increased consumption, but not abuse, of ethanol in essential tremor. J Neurol 2012;259(6):1177-80
21. Louis ED, Benito-Leon J, Bermejo-Pareja F. Population-based study of baseline ethanol consumption and risk of incident essential tremor. J Neurol Neurosurg Psychiatry 2009;80(5):494-7
22. Lind G, Schechtmann G, Lind C, et al. Subthalamic stimulation for essential tremor. Short-and long-term results and critical target area. Stereotact Funct Neurosurg 2008;86(4):253-8
23. Schuurman PR, Bosch DA, Bossuyt PM, et al. A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. N Engl J Med 2000;342(7):461-8
24. Schuurman PR, Bosch DA, Merkus MP, Speelman JD. Long-term follow-up of thalamic stimulation versus thalamotomy for tremor suppression. Mov Disord 2008;23(8):1146-53
25. Deuschl G. New treatment options for tremors. N Engl J Med 2000;342(7):505-7
26. Jimenez-Jimenez FJ, Alonso-Navarro H, Garcia-Martin E, et al. Update on genetics of essential tremor. Acta Neurol Scand 2013;128(6):359-71
27. Kuhlenbaumer G, Hopfner F, Deuschl G. Genetics of essential tremor: meta-analysis and review. Neurology 2014;82(11):1000-7
28. Schmouth JF, Dion PA, Rouleau GA. Genetics of essential tremor: From phenotype to genes, insights from both human and mouse studies. Prog Neurobiol 2014;119-120:1-19
29. Stefansson H, Steinberg S, Petursson H, et al. Variant in the sequence of the LINGO1 gene confers risk of essential tremor. Nat Genet 2009;41(3):277-9
30. Agundez JA, Jimenez-Jimenez FJ, Alonso-Navarro H, Garcia-Martin E. Genetic biomarkers of essential tremor: time to think outside of the box. Pharmacogenomics 2013;14(14):1681-2
31. Agundez JA, Jimenez-Jimenez FJ, Alonso-Navarro H, Garcia-Martin E. FUS: a putative biomarker for essential tremor raised by whole-exome sequencing analyses. Pharmacogenomics 2013;14(14):1680-1
32. Agundez JA, Jimenez-Jimenez FJ, Alonso-Navarro H, Garcia-Martin E. Genome-wide association study raised biomarker SLC1A2 rs3794087 and essential tremor: is it too early to say Pharmacogenomics 2013;14(14):1679-80
33. Ortega-Cubero S, Lorenzo-Betancor O, Lorenzo E, et al. Fused in Sarcoma (FUS) gene mutations are not a frequent cause of essential tremor in Europeans. Neurobiol Aging 2013;34(10):2441; e9-11
34. Thier S, Lorenz D, Nothnagel M, et al. Polymorphisms in the glial glutamate transporter SLC1A2 are associated with essential tremor. Neurology 2012;79(3):243-8
35. Merner ND, Girard SL, Catoire H, et al. Exome sequencing identifies FUS mutations as a cause of essential tremor. Am J Hum Genet 2012;91(2):313-19
36. Labbe C, Soto-Ortolaza AI, Rayaprolu S, et al. Investigating the role of FUS exonic variants in essential tremor. Parkinsonism Relat Disord 2013;19(8):755-7
37. Wu YR, Foo JN, Tan LC, et al. Identification of a novel risk variant in the FUS gene in essential tremor. Neurology 2013;81(6):541-4
38. Tan EK, Foo JN, Tan L, et al. SLC1A2 variant associated with essential tremor but not Parkinson disease in Chinese subjects. Neurology 2013;80(17):1618-19
39. Jimenez-Jimenez FJ, Garcia-Martin E, Lorenzo-Betancor O, et al. LINGO1 and risk for essential tremor: results of a meta-analysis of rs9652490 and rs11856808. J Neurol Sci 2012;317(1-2):52-7
40. Mi S, Lee X, Shao Z, et al. LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex. Nat Neurosci 2004;7(3):221-8
41. Mi S, Miller RH, Lee X, et al. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat Neurosci 2005;8(6):745-51
42. Inoue H, Lin L, Lee X, et al. Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease models. Proc Natl Acad Sci USA 2007;104(36):14430-5
43. Mi S, Pepinsky RB, Cadavid D. Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic. CNS Drugs 2013;27(7):493-503
44. Lee X, Shao Z, Sheng G, et al. LINGO-1 regulates oligodendrocyte differentiation by inhibiting ErbB2 translocation and activation in lipid rafts. Mol Cell Neurosci 2014;60:36-42
45. Fu QL, Hu B, Wu W, et al. Blocking LINGO-1 function promotes retinal ganglion cell survival following ocular hypertension and optic nerve transection. Invest Ophthalm Vis Sci 2008;49(3):975-85
46. Jepson S, Vought B, Gross CH, et al. LINGO-1, a transmembrane signaling protein, inhibits oligodendrocyte differentiation and myelination through intercellular self-interactions. J Biol Chem 2012;287(26):22184-95
47. Zhang Z, Xu X, Xiang Z, et al. LINGO-1 receptor promotes neuronal apoptosis by inhibiting WNK3 kinase activity. J Biol Chem 2013;288(17):12152-60
48. Lee X, Yang Z, Shao Z, et al. NGF regulates the expression of axonal LINGO-1 to inhibit oligodendrocyte differentiation and myelination. J Neurosci 2007;27(1):220-5
49. Fu QL, Hu B, Li X, et al. LINGO-1 negatively regulates TrkB phosphorylation after ocular hypertension. Eur J Neurosci 2010;31(6):1091-7
50. Mi S, Hu B, Hahm K, et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med 2007;13(10):1228-33
51. Mi S, Miller RH, Tang W, et al. Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann Neurol 2009;65(3):304-15
52. Fu QL, Li X, Yip HK, et al. Combined effect of brain-derived neurotrophic factor and LINGO-1 fusion protein on long-term survival of retinal ganglion cells in chronic glaucoma. Neuroscience 2009;162(2):375-82
53. Ji B, Li M, Wu WT, et al. LINGO-1 antagonist promotes functional recovery and axonal sprouting after spinal cord injury. Mol Cell Neurosci 2006;33(3):311-20
54. Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 2006;52(1):61-76
55. Pepinsky RB, Shao Z, Ji B, et al. Exposure levels of anti-LINGO-1 Li81 antibody in the central nervous system and dose-efficacy relationships in rat spinal cord remyelination models after systemic administration. J Pharmacol Exp Ther 2011;339(2):519-29
56. Loov C, Fernqvist M, Walmsley A, et al. Neutralization of LINGO-1 during in vitro differentiation of neural stem cells results in proliferation of immature neurons. PLoS One 2012;7(1):e29771
57. Minen MT, Louis ED. Emergence of Parkinson's disease in essential tremor: a study of the clinical correlates in 53 patients. Mov Disord 2008;23(11):1602-5
58. Louis ED, Frucht SJ. Prevalence of essential tremor in patients with Parkinson's disease vs. Parkinson-plus syndromes. Mov Disord 2007;22(10):1402-7
59. Tan EK, Lee SS, Fook-Chong S, Lum SY. Evidence of increased odds of essential tremor in Parkinson's disease. Mov Disord 2008;23(7):993-7
60. Benito-Leon J, Louis ED, Bermejo-Pareja F. Risk of incident Parkinson's disease and parkinsonism in essential tremor: a population based study. J Neurol Neurosurg Psychiatry 2009;80(4):423-5
61. Yahr MD, Orosz D, Purohit DP. Co-occurrence of essential tremor and Parkinson's disease: clinical study of a large kindred with autopsy findings. Parkinsonism Relat Disord 2003;9(4):225-31
62. Louis ED, Faust PL, Vonsattel JP, et al. Neuropathological changes in essential tremor: 33 cases compared with 21 controls. Brain 2007;130(Pt 12):3297-307
63. Jimenez-Jimenez FJ, Alonso-Navarro H, Garcia-Martin E, Agundez JA. The relationship between Parkinson's disease and essential tremor: review of clinical, epidemiologic, genetic, neuroimaging and neuropathological data, and data on the presence of cardinal signs of parkinsonism in essential tremor. Tremor Other Hyperkinet Mov 2012;2
64. Lauckaite K, Rastenyte D, Surkiene D, et al. Ultrasonographic (TCS) and clinical findings in overlapping phenotype of essential tremor and Parkinson's disease (ET-PD). BMC Neurol 2014;14:54
65. Pepinsky RB, Arndt JW, Quan C, et al. Structure of the LINGO-1-Anti-LINGO-1 Li81 antibody complex provides insights into the biology of LINGO-1 and the mechanism of action of the antibody therapy. J Pharmacol Exp Ther 2014;350(1):110-23
66. Tran JQ, Rana J, Barkhof F, et al. Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. Neurol Neuroimmunol Neuroinflamm 2014;1(2):e18
67. Konheim YL, Wolford JK. Association of a promoter variant in the inducible cyclooxygenase-2 gene (PTGS2) with type 2 diabetes mellitus in Pima Indians. Hum Genet 2003;113(5):377-81
68. Schonfeld SJ, Bhatti P, Brown EE, et al. Polymorphisms in oxidative stress and inflammation pathway genes, low-dose ionizing radiation, and the risk of breast cancer among US radiologic technologists. Cancer Causes Control 2010;21(11):1857-66
69. Agundez JA, Gonzalez-Alvarez DL, Vega-Rodriguez MA, et al. Gene variants and haplotypes modifying transcription factor binding sites in the human cyclooxygenase 1 and 2 (PTGS1 and PTGS2) genes. Curr Drug Metab 2014;15(2):182-95
70. Wu Y, Wang X, Xu W, et al. Genetic variation in LINGO-1 (rs9652490) and risk of Parkinson's disease: twelve studies and a meta-analysis. Neurosci Lett 2012;522(1):67-72
71. Agundez JA, Lorenzo-Betancor O, Pastor P, et al. LINGO1 rs9652490 and rs11856808 are not associated with the risk of Parkinson's disease: results of a meta-analysis. Parkinsonism Relat Disord 2012;18(5):657-9
72. Garcia-Martin E, Lorenzo-Betancor O, Martinez C, et al. LINGO1 rs9652490 and rs11856808 polymorphisms are not associated with risk for multiple sclerosis. BMC Neurol 2013;13:34
73. Tan EK, Teo YY, Prakash KM, et al. LINGO1 variant increases risk of familial essential tremor. Neurology 2009;73(14):1161-2
74. Vilarino-Guell C, Ross OA, Wider C, et al. LINGO1 rs9652490 is associated with essential tremor and Parkinson disease. Parkinsonism Relat Disord 2010;16(2):109-11
75. Thier S, Lorenz D, Nothnagel M, et al. LINGO1 polymorphisms are associated with essential tremor in Europeans. Mov Disord 2010;25(6):717-23
76. Vilarino-Guell C, Wider C, Ross OA, et al. LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson disease. Neurogenetics 2010;11(4):401-8
77. Clark LN, Park N, Kisselev S, et al. Replication of the LINGO1 gene association with essential tremor in a North American population. Eur J Hum Gen 2010;18(7):838-43
78. Zuo X, Jiang H, Guo JF, et al. Screening for two SNPs of LINGO1 gene in patients with essential tremor or sporadic Parkinson's disease in Chinese population. Neurosci Lett 2010;481(2):69-72
79. Wu YW, Rong TY, Li HH, et al. Analysis of Lingo1 variant in sporadic and familial essential tremor among Asians. Acta Neurol Scand 2011;124(4):264-8
80. Lorenzo-Betancor O, Garcia-Martin E, Cervantes S, et al. Lack of association of LINGO1 rs9652490 and rs11856808 SNPs with familial essential tremor. Eur J Neurol 2011;18(8):1085-9
81. Bourassa CV, Riviere JB, Dion PA, et al. LINGO1 variants in the French-Canadian population. PLoS One 2011;6(1):e16254
82. Radovica I, Inashkina I, Smeltere L, et al. Screening of 10 SNPs of LINGO1 gene in patients with essential tremor in the Latvian population. Parkinsonism Relat Disord 2012;18(1):93-5
83. Liang H, Song Z, Deng X, et al. Genetic analysis of the leucine-rich repeat and lg domain containing Nogo receptorinteracting protein 1 gene in essential tremor. J Mol Neurosc 2013;51(2):403-7
84. Zhou ZD, Sathiyamoorthy S, Tan EK. LINGO-1 and neurodegeneration: pathophysiologic clues for essential tremor. Tremor Other Hyperkinet Mov (N Y) 2012;2. pii: tre-02-51-249-1
85. Kuo SH, Tang G, Louis ED, et al. Lingo-1 expression is increased in essential tremor cerebellum and is present in the basket cell pinceau. Acta Neuropathol 2013;125(6):879-89
86. Delay C, Tremblay C, Brochu E, et al. Increased LINGO1 in the cerebellum of essential tremor patients. Mov Disord 2014;29(13):1637-47
87. Hutson TH, Foster E, Dawes JM, et al. Lentiviral vectors encoding short hairpin RNAs efficiently transduce and knockdown LINGO-1 but induce an interferon response and cytotoxicity in central nervous system neurones. J Gene Med 2012;14(5):299-315
88. Cao Z, Gao Y, Deng K, et al. Receptors for myelin inhibitors: structures and therapeutic opportunities. Mol Cell Neurosci 2010;43(1):1-14
89. Bourassa CV, Riviere JB, Dion PA, et al. LINGO1 variants in the French-Canadian population. PLoS One 2011;6(1):e16254
90. Liang H, Zheng W, Xu H, et al. No evidence of association between the LINGO4 gene and essential tremor in Chinese Han patients. Parkinsonism Relat Disord 2012;18(3):303-5